Q32 Bio (QTTB) Equity Average (2018 - 2026)

Q32 Bio has reported Equity Average for 9 years, with the latest figure at $44.2 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 5217.7% year-over-year to $44.2 million; the trailing twelve-month figure through Mar 2026 stood at $44.2 million (up 5217.7% YoY), and the FY2025 full-year result was $23.8 million, up 126.91% from the prior year.
• Equity Average for Q1 2026 stood at $44.2 million, up from $11.8 million in the prior quarter.
• The five-year high for Equity Average was $253.3 million in Q2 2022, with the low at -$169.7 million in Q4 2023.
• Average Equity Average over 5 years is $11.0 million, with a median of $11.8 million recorded in 2025.
• Year-over-year, Equity Average slumped 533.15% in 2023 and soared 5217.7% in 2026.
• Tracing QTTB's Equity Average over 5 years: stood at $39.2 million in 2022, then tumbled by 533.15% to -$169.7 million in 2023, then jumped by 107.06% to $12.0 million in 2024, then decreased by 1.69% to $11.8 million in 2025, then surged by 274.81% to $44.2 million in 2026.
• The last three Equity Average figures came in at $44.2 million (Q1 2026), $11.8 million (Q4 2025), and -$15.3 million (Q3 2025), per Business Quant data.

Peer Comparison